Table 1. Baseline Characteristics of Participants.
| Characteristic | Isoflavone Group n = 42 men | Placebo Group n = 44 men |
| Mean age, y (sd) | 62±12 | 62±7 |
| Race, No. (%) | ||
| White | 38 (90) | 31 (70) |
| Black | 3 (7) | 9 (20) |
| American Indian or Alaska Native | 1(2) | 4 (9) |
| Asian/Pacific Islander | 0 | 0 |
| Ethnicity, No. (%) | ||
| Hispanic | 1 (2) | 2 (5) |
| Non-Hispanic | 41 (98) | 42 (95) |
| Clinical Stage, No. (%)1 | ||
| T1 | 15 (35) | 24 (55) |
| T2 | 27 (64) | 19 (43) |
| Mean baseline PSA, ng/mL (SD) | 9±5 | 8±4 |
| Gleason Score, No. (SD) | 7±0.9 | 7±0.7 |
| Body weight, pds (SD) | 208±40 | 213±41 |
| Height, in (SD) | 70±2 | 70±3 |
| BMI, kg/m2 (SD) | 30±5 | 31±5 |
| Physical Activity | ||
| ≥15 min exercise/day, No. (%) | 8 (19) | 6 (14) |
| <15 min exercise/day, No. (%) | 34 (81) | 37 (86) |
Baseline characteristics were compared using t-tests for continuous variables after checking normality assumptions and Fisher’s Exact test for categorical variables. P<0.05 was considered statistically significant. PSA = prostate-specific antigen; BMI = Body Mass Index.
1
Clinical stage based on the American Joint Committee on Cancer criteria.